Votrient (pazopanib) — United Healthcare

Initial criteria

• Diagnosis of uterine sarcoma AND (disease is advanced OR recurrent/metastatic OR inoperable)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Votrient therapy

Approval duration

12 months